Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | IGF2R | P11717 | 4/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
| ▸ | UMPS | P11172 | 2/20 | 0.39 |
| ▸ | ATIC | P31939 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25084084 | 1.00 | AMDHD2 (0.74) | AMDHD2FBP1IGF2RP2RY2P2RY6 | |
| SCHEMBL29394667 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL4363206 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL29425232 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL25361382 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL4363197 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL14669223 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL20558753 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL20912983 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 | |
| SCHEMBL20291477 | 0.84 | AMDHD2 (0.68) | AMDHD2FBP1IGF2RP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324123-A1 | GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES | GLMN, RNGTT, GMPS | AMDHD2 140/4885FBP1 136/4885IGF2R 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.